Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
UBS
Medtronic
Harvard Business School
Cipla
Chinese Patent Office
US Army
QuintilesIMS
Covington

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,635,485

« Back to Dashboard

Which drugs does patent 5,635,485 protect, and when does it expire?

Patent 5,635,485 protects KETEK and is included in one NDA.

This patent has sixty-two patent family members in thirty-nine countries.
Summary for Patent: 5,635,485
Title: Erythromycin compounds
Abstract:An erythromycin compound of Formula I or its non-toxic acid addition salt having antibiotic activity.
Inventor(s): Agouridas; Constantin (Nogent sur Maine, FR), Chantot; Jean-Francois (Nogent sur Maine, FR), Denis; Alexis (Paris, FR), D'Ambrieres; Solange G. (Paris, FR), Martret; Odile L. (Paris, FR)
Assignee: Roussel Uclaf (FR)
Application Number:08/426,067
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,635,485

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-002 Feb 9, 2005 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER. ➤ Try a Free Trial
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-001 Apr 1, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER. ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,635,485

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France94 05368May 03, 1994

Non-Orange Book US Patents Family Members for Patent 5,635,485

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,100,404 Erythromycin compounds ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 5,635,485

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 558 ➤ Try a Free Trial
African Regional IP Organization (ARIPO) 9500744 ➤ Try a Free Trial
Austria 172203 ➤ Try a Free Trial
Australia 2449995 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Argus Health
Merck
Fuji
Teva
US Department of Justice
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.